PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging (Q31162100)

17 August 2017

PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging (English)

1 reference

17 August 2017

1 reference

3

Luigi Ferrucci

1 reference

17 August 2017

6

H Ballentine Carter

1 reference

17 August 2017

4

Patricia Landis

1 reference

17 August 2017

Stacy Loeb

1

1 reference

17 August 2017

Anna Kettermann

series ordinal

2

1 reference

17 August 2017

E Jeffrey Metter

series ordinal

5

1 reference

17 August 2017

language of work or name

English

0 references

publication date

2 July 2008

1 reference

17 August 2017

1 reference

17 August 2017

54

1 reference

17 August 2017

1073-1080

1 reference

17 August 2017

5

1 reference

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Active surveillance for prostate cancer: for whom?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Analysis of correlated ROC areas in diagnostic testing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Sampling variability of nonparametric estimates of the areas under receiver operating characteristic curves: an update.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582974

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome

31 October 2018

1 reference

12 December 2020

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

1 reference

12 December 2020

Methods of calculating prostate-specific antigen velocity

1 reference

12 December 2020

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era

1 reference

12 December 2020

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

1 reference

12 December 2020

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy

1 reference

12 December 2020

Does PSA velocity predict prostate cancer in pre-screened populations?

1 reference

12 December 2020

PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence

1 reference

12 December 2020

10.1016/J.EURURO.2008.06.076

Identifiers

DOI

1 reference

17 August 2017

1 reference

17 August 2017

1 reference